NABOTA Trademark

Trademark Overview


On Friday, April 12, 2013, a trademark application was filed for NABOTA with the United States Patent and Trademark Office. The USPTO has given the NABOTA trademark a serial number of 85902409. The federal status of this trademark filing is CANCELLED - SECTION 7 as of Thursday, January 14, 2021. This trademark is owned by DAEWOONG PHARMACEUTICAL CO., LTD.. The NABOTA trademark is filed in the Pharmaceutical Products category with the following description:

Botulinum toxin for medical use for use in the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, pelvic pain and urge type dysfunction; Pharmaceutical preparations, namely, acne medications, acne treatment preparations, adrenal hormone preparations, alcohol for topical use, allergy and allergy relief medications, analgesics, androgen preparations, anesthetics for surgical and non-surgical use, antacids, bactericides, antiarrhythmics, antibiotics, anticoagulants, anticonvulsants, antidepressants, antidiabetic preparations, antivirals, anti-cancer preparations, anti-infectives, anti-inflammatories, antipyretics, antibacterial pharmaceuticals, calcium channel blockers, beta blockers, chemical compounds for drug delivery, e...
nabota

General Information


Serial Number85902409
Word MarkNABOTA
Filing DateFriday, April 12, 2013
Status711 - CANCELLED - SECTION 7
Status DateThursday, January 14, 2021
Registration Number4535957
Registration DateTuesday, May 27, 2014
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 11, 2014

Trademark Statements


Indication of Colors claimedColor is not claimed as a feature of the mark.
Goods and ServicesBotulinum toxin for medical use for use in the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, pelvic pain and urge type dysfunction; Pharmaceutical preparations, namely, acne medications, acne treatment preparations, adrenal hormone preparations, alcohol for topical use, allergy and allergy relief medications, analgesics, androgen preparations, anesthetics for surgical and non-surgical use, antacids, bactericides, antiarrhythmics, antibiotics, anticoagulants, anticonvulsants, antidepressants, antidiabetic preparations, antivirals, anti-cancer preparations, anti-infectives, anti-inflammatories, antipyretics, antibacterial pharmaceuticals, calcium channel blockers, beta blockers, chemical compounds for drug delivery, eye drops, eye patches for medical purposes, hair growth stimulants, vaccines, vaccine adjuvants, vaccine stabilizers, diuretics, amino acids for medical purposes; Medicines for the treatment of gastrointestinal diseases; chemical preparations for pharmaceutical purposes for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, pelvic pain and urge type dysfunction; chemico-pharmaceutical preparations for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, pelvic pain and urge type dysfunction; drugs for medical purposes for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, pelvic pain and urge type dysfunction; Medicines for human purposes for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, pelvic pain and urge type dysfunction; pharmaceutical preparations for activating cellular function; Adjuvants for medical purposes; pharmaceutical preparations for central nerve treatment; pharmaceutical preparations for diagnosis; dermatological pharmaceutical products; pharmaceutical preparations for treating skin disorders; antibiotic preparations; pharmaceutical preparations for respiratory organs; pharmaceutical preparations for chemical disorder treatment

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code1 - Sec. 7(d) - Entire Registration
Class Status DateThursday, January 14, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameDAEWOONG PHARMACEUTICAL CO., LTD.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressGyeonggi-do 18623
KR

Party NameDAEWOONG PHARMACEUTICAL CO., LTD.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSungnam-city Kyunggido
KR

Party NameDAEWOONG PHARMACEUTICAL CO., LTD.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSungnam-city Kyunggido
KR

Trademark Events


Event DateEvent Description
Friday, January 15, 2021NOTICE OF CANCELLATION SEC. 7 SURRENDER EMAILED
Thursday, January 14, 2021CANCELLED SECTION 7-TOTAL
Monday, October 19, 2020REQUEST FOR SECT 7 TOTAL SURRENDER FILED
Friday, January 8, 2021CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Monday, October 19, 2020TEAS SECTION 7 SURRENDER RECEIVED
Monday, October 19, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, October 19, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, October 19, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, October 19, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, October 19, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, May 27, 2019COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, May 27, 2014REGISTERED-PRINCIPAL REGISTER
Tuesday, March 11, 2014OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 11, 2014PUBLISHED FOR OPPOSITION
Wednesday, February 19, 2014NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 4, 2014LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, January 29, 2014APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, January 28, 2014TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, January 28, 2014CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 21, 2014ASSIGNED TO LIE
Monday, December 30, 2013TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, July 30, 2013NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, July 30, 2013NON-FINAL ACTION E-MAILED
Tuesday, July 30, 2013NON-FINAL ACTION WRITTEN
Monday, July 29, 2013ASSIGNED TO EXAMINER
Thursday, April 18, 2013NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, April 16, 2013NEW APPLICATION ENTERED IN TRAM